donepezil   Click here for help

GtoPdb Ligand ID: 6599

Synonyms: Aricept® | E-2020
Approved drug
donepezil is an approved drug (FDA (1996))
Compound class: Synthetic organic
Comment: May be refered to as donepezil hydrochloride (PubChem CID 5741). In addition to the original brand, Aricept, generic donepezil formulations are now approved by the US FDA.
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: donepezil

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 0
Rotatable bonds 6
Topological polar surface area 38.77
Molecular weight 379.21
XLogP 3.67
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1cc2c(cc1OC)CC(C2=O)CC1CCN(CC1)Cc1ccccc1
Isomeric SMILES COc1cc2c(cc1OC)CC(C2=O)CC1CCN(CC1)Cc1ccccc1
InChI InChI=1S/C24H29NO3/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18/h3-7,14-15,17,20H,8-13,16H2,1-2H3
InChI Key ADEBPBSSDYVVLD-UHFFFAOYSA-N
References
1. Cardozo MG, Iimura Y, Sugimoto H, Yamanishi Y, Hopfinger AJ. (1992)
QSAR analyses of the substituted indanone and benzylpiperidine rings of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase.
J Med Chem, 35 (3): 584-9. [PMID:1738151]
2. Galli A, Mori F, Benini L, Cacciarelli N. (1994)
Acetylcholinesterase protection and the anti-diisopropylfluorophosphate efficacy of E2020.
Eur J Pharmacol, 270 (2-3): 189-93. [PMID:8039548]
3. Luo W, Yu QS, Kulkarni SS, Parrish DA, Holloway HW, Tweedie D, Shafferman A, Lahiri DK, Brossi A, Greig NH. (2006)
Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine.
J Med Chem, 49 (7): 2174-85. [PMID:16570913]
4. Sabbagh M, Cummings J, Christensen D, Doody R, Farlow M, Liu L, Mackell J, Fain R. (2013)
Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response.
BMC Geriatr, 13: 56. [PMID:23742728]